From Surf Wiki (app.surf) — the open knowledge base
Fosazepam
Benzodiazepam
Benzodiazepam
| Field | Value | |||||
|---|---|---|---|---|---|---|
| Watchedfields | changed | |||||
| verifiedrevid | 455325548 | |||||
| IUPAC_name | 7-chloro-1-(dimethylphosphorylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one | |||||
| image | Fosazepam.svg | |||||
| image_class | skin-invert-image | |||||
| width | 190 | |||||
| CAS_number_Ref | ||||||
| CAS_number | 35322-07-7 | |||||
| ATC_prefix | none | |||||
| PubChem | 37114 | |||||
| DrugBank_Ref | ||||||
| ChemSpiderID_Ref | ||||||
| ChemSpiderID | 34056 | |||||
| UNII_Ref | ||||||
| UNII | 13AK3H33SG | |||||
| KEGG_Ref | ||||||
| KEGG | D04248 | |||||
| C | 18 | H=18 | Cl=1 | N=2 | O=2 | P=1 |
| smiles | ClC1=CC2=C(C=C1)N(CP(C)(C)=O)C(CN=C2C3=CC=CC=C3)=O | |||||
| StdInChI_Ref | ||||||
| StdInChI | 1S/C18H18ClN2O2P/c1-24(2,23)12-21-16-9-8-14(19)10-15(16)18(20-11-17(21)22)13-6-4-3-5-7-13/h3-10H,11-12H2,1-2H3 | |||||
| StdInChIKey_Ref | ||||||
| StdInChIKey | JMYCGCXYZZHWMO-UHFFFAOYSA-N |
| elimination_half-life =
Fosazepam is a drug belonging to the benzodiazepine class, which are primarily anti-anxiety and sedative-hypnotic agents. It is a water soluble derivative of diazepam which has been substituted with a dimethylphosphoryl group to improve solubility in water. At equipotent doses (100 mg fosazepam and 10 mg diazepam), it possesses sedative and anxiolytic properties that are qualitatively and quantitatively similar to the effects of diazepam, with equal sedative-hypnotic, anti-convulsive, and muscle relaxant effects. In comparison to an equipotent dose of nitrazepam (100 mg fosazepam and 10 mg nitrazepam), its effects tended to be of noticeably milder magnitude.
Fosazepam has similar effects on sleep as other benzodiazepines. In a clinical trial it was reported that fosazepam to lead to increased sleep duration with less broken sleep but sleep quality was worsened with suppressed deep sleep and increased light sleep. Adverse effects included feelings of impaired morning vitality and upon discontinuing the drug benzodiazepine withdrawal symptoms of anxiety, impaired concentration and impaired morning vitality were experienced. Another clinical trial also found worsening of sleep while on benzodiazepines as well as during withdrawal with suppression of deep sleep stages including REM sleep, with increased light sleep upon withdrawal. The main metabolites of fosazepam are 3-hydroxyfosazepam and the active metabolite desmethyldiazepam which has a very long elimination half-life of about 3 days. Tolerance to the hypnotic effects of fosazepam starts to develop after about 7 days of use. Due to the very long elimination half-life of the active metabolite of fosazepam it is not recommended for use as a hypnotic. The main pharmacological effects of fosazepam may be due to its metabolite nordiazepam (desmethyldiazepam), rather than the parent drug. The long-acting active metabolite nordazepam can cause extended sedative effects at high doses or with prolonged use, and may produce residual sedation upon awakening.
Fosazepam is of relatively low potency compared to other benzodiazepine derivatives, with a 100 mg dose of fosazepam equivalent to 10 mg of diazepam and 10 mg nitrazepam. 60 mg of fosazepam has also been estimated to be equivalent to about 6 mg of diazepam. Fosazepam has similar effects to nitrazepam, but with a shorter duration of action and less tendency to cause over sedation, motor-impairment, amnesia, rebound insomnia, and morning grogginess.
References
References
- DE Patent 2022503
- (August 1977). "Activity of fosazepam, a soluble analogue of diazepam". British Journal of Clinical Pharmacology.
- (October 1975). "Proceedings: Effect of diazepam and a soluble salt of diazepam (fosazepam) on sleep in man". British Journal of Pharmacology.
- (February 1976). "Anxiety and sleep after fosazepam". British Journal of Clinical Pharmacology.
- (January 1978). "Efficacy and side effects of flurazepam, fosazepam, and nitrazepam as sleeping aids in psychogeriatric patients". Acta Psychiatrica Scandinavica.
- (1980). "Pharmacokinetics of benzodiazepines. Short-acting versus long-acting". Arzneimittel-Forschung.
- (October 1977). "Evaulation of the effect of fosazepam (a new benzodiazepine), nitrazepam and placebo on sleep patterns in normal subjects". European Journal of Clinical Pharmacology.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Fosazepam — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report